logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Antiretroviral drugs as a public health intervention for pregnant HIV-infected women in rural South Africa : an issue of cost-effectiveness and capacity.

    Article - En anglais

    Objective 

    To estimate cost-effectiveness and capacity requirements for providing antiretroviral drugs to pregnant HIV-infected women in rural South Africa.

    Setting 

    Hlabisa health district, where HIV prevalence among pregnant women was 26.0% in 1997.

    Methods 

    Calculation of the number of paediatric HIV infections averted under three scenarios, and their cost.

    No intervention was compared with scenario A (zidovudine delivered within current infrastructure), scenario B (zidovudine delivered through enhanced infrastructure), and scenario C (short-course zidovudine plus lamivudine delivered through enhanced infrastructure).

    Cost-effectiveness was defined as cost per infection averted and cost per potential life-year gained.

    Capacity was determined in terms of staff and infrastructure required to effectively implement the scenarios.

    Results 

    With no intervention, 657 paediatric HIV infections were projected for 1997.

    In scenario A this could be reduced by 15% at a cost of USS 574 825, in scenario B by 42% at US$ 1 520 770, and in scenario C by 47% at US$ 764 901.

    In scenario C, drugs accounted for 76% of costs, whereas additional staff accounted for 18%. Cost per infection averted was US$ 2492 and cost per potential life-year gained (discounted at 3%) was US$ 88.

    Cost of scenario C was equivalent to 14% of the 1997 district health budget. (...)

    Mots-clés Pascal : SIDA, Virose, Infection, Transmission mère enfant, Chimiothérapie, Zidovudine, Lamivudine, Chimioprophylaxie, Gestation, Prévention, Traitement, Analyse coût efficacité, Programme sanitaire, Femelle, Homme, République Sud Africaine, Afrique, Zone rurale, Antiviral, Pyrimidine nucléoside, Didésoxynucléoside, Immunopathologie, Immunodéficit, Economie santé, Transmission verticale

    Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Mother to child transmission, Chemotherapy, Zidovudine, Lamivudine, Chemoprophylaxis, Pregnancy, Prevention, Treatment, Cost efficiency analysis, Sanitary program, Female, Human, South Africa, Africa, Rural area, Antiviral, Pyrimidine nucleoside, Dideoxynucleoside, Immunopathology, Immune deficiency, Health economy

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0434147

    Code Inist : 002B02S05. Création : 25/01/1999.